Novo Nordisk (Clayton, NC facility)
Bagsværd, Denmark (US manufacturing: Clayton, NC)
Program data pending ClinicalTrials.gov matching
57.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (1)
○ EMA GMP
○ MHRA GMP
Quick Facts: Novo Nordisk (Clayton, NC facility)
- Signal Score
- 57.5/100
- Quality Compliance
- Assessment pending
- Headquarters
- Bagsværd, Denmark (US manufacturing: Clayton, NC)
- Modalities
- Peptide API (recombinant/yeast-based), Sterile Fill-Finish, Drug Product (injectable pen, oral tablet)
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Novo Nordisk (Clayton, NC facility)
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesPeptide API (recombinant/yeast-based), Sterile Fill-Finish, Drug Product (injectable pen, oral tablet)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
55.0
Manufacturing site information being gathered
Modalities: Peptide API (recombinant/yeast-based), Sterile Fill-Finish, Drug Product (injectable pen, oral tablet)
Capacity assessment: 55.0/100
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press1 articles
Manufacturing site information being gathered
Modalities: Peptide API (recombinant/yeast-based), Sterile Fill-Finish, Drug Product (injectable pen, oral tablet)
Capacity assessment: 55.0/100
Recent News 1 articles
Inside the FDA's Form 483 findings at Novo Nordisk's North Carolina semaglutide plant - Fierce Pharma
Frequently Asked Questions About Novo Nordisk (Clayton, NC facility)
What is Novo Nordisk (Clayton, NC facility)'s CDMO Signal Score?
Novo Nordisk (Clayton, NC facility) has a Signal Score of 58/100, based on quality, operations, financial stability, and capacity data.
Evaluating Novo Nordisk (Clayton, NC facility) for a manufacturing program?
Use the free AI matchmaker to compare Novo Nordisk (Clayton, NC facility) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
Similar CDMOs
BioCina
Adelaide, Australia
Biologics (Microbial), Plasmid DNA, mRNA, LNP, Sterile Fill-Finish, Recombinant Proteins, Vaccines, Biosimilars, High Potency/Oncology Injectables, Blow-Fill-Seal
Bryllan LLC
Brighton, MI
Sterile Fill-Finish, Aseptic Powder & Liquid Filling, Biologics (Injectables), Potent/Cytotoxic Compounds, Hormones, mAbs/Antibodies, Live Viruses, Vaccines, Drug-Device Combination Products (Syringes, IV Bags, Cartridges)
Mabion S.A.
Konstantynów Łódźki, Poland
Monoclonal Antibody, Recombinant Protein, Biosimilars, Vaccine Antigens, ADC / PDC (analytics & development), Sterile Fill-Finish
Kemwell Biopharma
Bengaluru, India
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Biosimilars, Cell Therapy, Sterile Fill-Finish
Kemwell Biopharma, Bangalore
Bengaluru, India
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Biosimilars, Cell Therapy, Sterile Fill-Finish, Lyophilized Drug Product